Security
Iovance Biotherapeutics, Inc. Common Stock · IOVA
IOVANASDAQCommon stockCurrentCIK 1425205Updated Oct 6, 2026
Name history
Lion Biotechnologies, Inc. · through Jun 5, 2017Genesis Biopharma, Inc · through Sep 23, 2013FREIGHT MANAGEMENT CORP · through Mar 8, 2010
IOVA price & chart
Loading TradingView…
NASDAQ:IOVA on TradingView ↗About the company
Iovance Biotherapeutics, Inc. is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi® (lifileucel) is the first FDA-approved, one-time treatment for previously treated advanced melanoma, now approved in three global markets and available at nearly 100 authorized treatment centers (ATCs). The Iovance TIL platform spans registrational trials and next-generation programs in additional solid tumors, including gene-edited and IL-12 tethered TIL therapies, next-generation IL-2, and precision immuno-oncology approaches. As the first and only company to take TIL therapy from concept to a broadly accessible commercial treatment, Iovance operates as an end-to-end cell therapy company, anchored by fully owned, centralized U.S.-based manufacturing that is scaled to serve thousands of cancer patients worldwide each year. Headquartered in Pennsylvania with offices and laboratories in California and Florida, Iovance serves patients at ATCs and clinical sites across almost the entire U.S. and in many countries around the world. For more information, please visit www.iovance.com.
In the news
High-Stakes October has these Biotechs Entering Crucial Stretch ↗
Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment News provided by USA News Group Aug 14, 2025, 12:22 ET Share this article Share to X Share this article Share to X USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC , Aug. 14, 2025 /PRNew ↗
IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV News provided by DJS Law Group LLP Jul 14, 2025, 09:04 ET Share this article Share to X Share this article Share to X LOS ANGELES , July 14, 2025 /PR ↗
Recent filings
Other Events
Items 8.01, 9.01
4 filing
3 filing
Other Events
Items 8.01, 9.01
Other Events
Items 8.01, 9.01
Show 5 more recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Other Events
Items 8.01, 9.01
4 filing
4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 913,170,000Source | 910,426,000Source | 780,351,000Source | 663,982,000Source |
| Property, Plant and Equipment, NetUSD | 131,112,000Source | 109,081,000Source | 114,030,000Source | 105,232,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 163,078,000Source | 115,694,000Source | 114,888,000Source | 231,731,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 82,448,000Source | 69,340,000Source | 151,000Source | — |
| Inventory, NetUSD | 51,678,000Source | 51,520,000Source | 10,372,000Source | — |
| Assets, CurrentUSD | 442,689,000Source | 457,018,000Source | 307,848,000Source | 479,116,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 11,583,000Source | 12,377,000Source | 17,458,000Source | 7,271,000Source |
| Operating Lease, Right-of-Use AssetUSD | 45,899,000Source | 55,201,000Source | 62,515,000Source | 73,015,000Source |
| Other Assets, NoncurrentUSD | 8,166,000Source | 369,000Source | 270,000Source | 189,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 214,587,000Source | 200,021,000Source | 195,738,000Source | 164,344,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 17,000Source | 13,000Source | 11,000Source | 8,000Source |
| Additional Paid in CapitalUSD | 3,457,654,000Source | 3,095,987,000Source | 2,594,448,000Source | 2,068,867,000Source |
| Retained Earnings (Accumulated Deficit)USD | -2,775,530,000Source | -2,384,552,000Source | -2,012,375,000Source | -1,568,338,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 16,440,000Source | -1,046,000Source | 2,526,000Source | -902,000Source |
| Stockholders' Equity Attributable to ParentUSD | 698,583,000Source | 710,405,000Source | 584,613,000Source | 499,638,000Source |
| Liabilities and EquityUSD | 913,170,000Source | 910,426,000Source | 780,351,000Source | 663,982,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 138,358,000Source | 122,341,000Source | 110,306,000Source | 91,485,000Source |
| Operating Lease, Liability, CurrentUSD | 4,043,000Source | 12,896,000Source | 7,777,000Source | 12,587,000Source |
| Accounts Payable, CurrentUSD | 22,159,000Source | 27,509,000Source | 33,123,000Source | 26,603,000Source |
| Operating Lease, Liability, NoncurrentUSD | 44,401,000Source | 44,365,000Source | 67,085,000Source | 71,859,000Source |
| Deferred Income Tax Liabilities, NetUSD | 31,828,000Source | 32,315,000Source | 17,347,000Source | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 111,156,000Source | 81,936,000Source | 69,406,000Source | 52,295,000Source |
| Deferred Tax Liabilities, NetUSD | 31,828,000Source | 32,315,000Source | 17,347,000Source | — |
| Short-term InvestmentsUSD | 133,902,000Source | 208,087,000Source | 164,979,000Source | 240,114,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 12,862,000Source | 11,967,000Source | 11,568,000Source | 9,310,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 61,575,000Source | 109,627,000Source | 62,625,000Source | 84,022,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 13,108,000Source | 69,189,000Source | 149,000Source | — |
| Increase (Decrease) in InventoriesUSD | 14,211,000Source | 39,917,000Source | 10,118,000Source | — |
| Increase (Decrease) in Accounts PayableUSD | -6,661,000Source | -7,841,000Source | 4,828,000Source | 5,883,000Source |
| Deferred Income Tax Expense (Benefit)USD | -2,071,000Source | -2,828,000Source | -3,479,000Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -302,408,000Source | -352,977,000Source | -361,820,000Source | -292,757,000Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | 212,633,000Source | — |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 47,496,000Source | -96,411,000Source | -155,242,000Source | 256,455,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 33,836,000Source | 11,069,000Source | 22,290,000Source | 20,425,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 7,059,000Source | 12,858,000Source | 2,795,000Source | 2,649,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 300,773,000Source | 390,664,000Source | 462,959,000Source | 190,150,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 47,005,000Source | -59,265,000Source | -56,843,000Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 169,058,000Source | 122,053,000Source | 181,318,000Source | 238,161,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | 0Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 1,144,000Source | -541,000Source | -2,740,000Source | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 23,077,000Source | 21,202,000Source | 9,849,000Source | — |
| DepreciationUSD | — | — | — | 9,300,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 238,000Source | 175,000Source | -70,000Source | — |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | — | — | — | -397,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -44,000Source | — | — | — |
| Gain (Loss) on Termination of LeaseUSD | — | 5,568,000Source | — | — |
| General and Administrative ExpenseUSD | 152,322,000Source | 153,017,000Source | 106,916,000Source | 104,097,000Source |
| Income Tax Expense (Benefit)USD | -2,071,000Source | -2,828,000Source | -3,479,000Source | — |
| Inventory Write-downUSD | 13,404,000Source | — | — | — |
| Investment Income, InterestUSD | 10,307,000Source | 20,273,000Source | 13,043,000Source | 2,985,000Source |
| Net Income (Loss) Attributable to ParentUSD | -390,978,000Source | -372,177,000Source | -444,037,000Source | -395,893,000Source |
| Operating ExpensesUSD | — | — | — | 398,878,000Source |
| Proceeds from Issuance of Common StockUSD | 306,307,000Source | 397,304,000Source | 463,281,000Source | 189,502,000Source |
| Proceeds from Stock Options ExercisedUSD | 15,000Source | 3,266,000Source | 63,000Source | 1,642,000Source |
| Share-based Payment Arrangement, Expensed and Capitalized, AmountUSD | 61,575,000Source | 109,623,000Source | 62,625,000Source | 84,022,000Source |
| Unrealized Gain (Loss) on InvestmentsUSD | 54,000Source | 78,000Source | 940,000Source | -301,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 263,502,000Source | 164,070,000Source | 1,189,000Source | — |
| Cost of Goods and Services Sold | — | — | — | — |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Operating Income (Loss)USD | -403,356,000Source | -395,278,000Source | -460,559,000Source | -398,878,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -393,049,000Source | -375,005,000Source | -447,516,000Source | — |
| Income Tax Expense (Benefit)USD | -2,071,000Source | -2,828,000Source | -3,479,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | -390,978,000Source | -372,177,000Source | -444,037,000Source | -395,893,000Source |
| Earnings Per Share, BasicUSD per share | -1.09Source | -1.28Source | -1.89Source | -2.49Source |
| Earnings Per Share, DilutedUSD per share | -1.09Source | -1.28Source | -1.89Source | -2.49Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 357,345Source | 289,877Source | 235,131Source | 159,259Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 357,345Source | 289,877Source | 235,131Source | 159,259Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 23,077,000Source | 21,202,000Source | 9,849,000Source | — |
| Costs and ExpensesUSD | 666,858,000Source | 559,348,000Source | 461,748,000Source | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | 35,939,000Source | — | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 238,000Source | 175,000Source | -70,000Source | — |
| General and Administrative ExpenseUSD | 152,322,000Source | 153,017,000Source | 106,916,000Source | 104,097,000Source |
| Investment Income, InterestUSD | 10,307,000Source | 20,273,000Source | 13,043,000Source | 2,985,000Source |
| Operating ExpensesUSD | — | — | — | 398,878,000Source |
| Research and Development ExpenseUSD | 300,270,000Source | 282,336,000Source | 344,077,000Source | 294,781,000Source |
| Share-based Payment Arrangement, Expensed and Capitalized, AmountUSD | 61,575,000Source | 109,623,000Source | 62,625,000Source | 84,022,000Source |
Offerings
Registration 333-296908
Filing attachments
tm2627047d1_ex99-1.htm · 8-K · 2026-10-05
Exhibit 99.1 1 © 2026, Iovance Biotherapeutics, Inc. © 2026, Iovance Biotherapeutics, Inc. Corporate Overview October 2026 1 2 © 2026, Iovance Biotherapeutics, Inc. Forward - Looking Statements Certain matters discussed in this presentation are “forward - looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we…
Read attachment ↗tm2626507d1_ex99-1.htm · 8-K · 2026-09-29
Exhibit 99.1 Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million New Guidance Represents an Increase of $55 Million at the Midpoint from the Prior Range of $350 to $370 Million Strong U.S. Demand for Amtagvi and Proleukin Drives Increased Outlook PHILADELPHIA, Pennsylvania, September 29, 2026 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrati…
Read attachment ↗tm2622463d1_ex99-1.htm · 8-K · 2026-08-06
EX-99.1 2 tm2622463d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 1 © 2026, Iovance Biotherapeutics, Inc. Corporate Overview August 2026 1 ───────────────────────────────────────── 2 © 2026, Iovance Biotherapeutics, Inc. Forward-Looking Statements Certain matters discussed in this presentation are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigatio…
Read attachment ↗tm2622322d1_ex99-1.htm · 8-K · 2026-08-06
EX-99.1 2 tm2622322d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates U.S. Amtagvi Revenue Reaches ~$91M and Total Revenue Increased 66% Year-over-Year Gross Margin Increased to 56% Fast Track Designation (FTD) Granted by the FDA for Lifileucel in Soft Tissue Sarcomas SAN CARLOS, Calif., August 6, 2026 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology…
Read attachment ↗tm2618989d1_ex99-1.htm · 8-K · 2026-07-02
EX-99.1 2 tm2618989d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 1 © 2026, Iovance Biotherapeutics, Inc. © 2026, Iovance Biotherapeutics, Inc. Corporate Overview June 2026 1 2 © 2026, Iovance Biotherapeutics, Inc. Forward - Looking Statements Certain matters discussed in this presentation are “forward - looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (t…
Read attachment ↗tm2618119d2_ex99-1.htm · S-8 · 2026-06-18
Exhibit 99.1 IOVANCE BIOTHERAPEUTICS, INC. 2020 EMPLOYEE STOCK PURCHASE PLAN AS AMENDED 1. Establishment, Purpose and Term of Plan. 1.1 Establishment. The Iovance Biotherapeutics, Inc. 2020 Employee Stock Purchase Plan (as amended from time to time, the “Plan”) is hereby established effective as of June 8, 2020, the date of its initial approval by the stockholders of the Company (the “Effective Date”). 1.2 Purpose. The purpose of the Plan is to advance the…
Read attachment ↗